View all newsletters
Receive our newsletter - data, insights and analysis delivered to you

Getting Up to Date with Complex Generics

Are you up-to-date on complex generics? You probably already know they are inherently difficult to duplicate, yet still reviewed by CDER-OGD (not CBER) using 505(j) Abbreviated New Drug Applications (ANDAs).

Complex generics represent an emerging market, largely because of the higher barriers to entry. Although akin to Biosimilars, the ANDA pathway is not always clear.

Hence, as with the development of biosimilars, complex generics require a substantial commitment of resources.

If you don’t have staff well-versed in their regulatory complexity, hiring a consultant who has experience with complex generics can make a substantial difference in managing resources, mitigating risks and developing methods to demonstrate sameness.

To read more about complex generics, click here.

Clinical trial consulting and pharmaceutical consulting professionals will benefit by becoming current on adaptive trial design.
Safety surveillance and pharmacovigilance consulting to generic drug manufacturers, as well as generic drug labelling consulting may soon become a service in demand.
Pharmaceutical Development Group (PDG) is a drug and medical device consultant that continuously engages in meetings and interactions with the US Food and Drug Administration...
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy


Thank you for subscribing to Pharmaceutical Technology